Relief has announced that its U.S. Collaboration Partner has filed a Provisional Patent for Stable Aviptadil Compositions Suitable for Human Use.
NRx Pharmaceuticals, Inc. (“NRx”), the parent company of RELIEF THERAPEUTICS Holding SA (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced today that NeuroRx, Inc. (“NeuroRx”), its collaboration partner for aviptadil, has filed a provisional composition of matter patent application with the US Patent and Trademark Office. According to the press announcement, the provisional application describes compositions of aviptadil, a vasoactive intestinal peptide, that are both shelf stable and biologically active when used to treat COVID-19 and other illnesses.
In response to NRx’s press release claiming that aviptadil is a 70-year-old dormant drug, Relief points out that aviptadil is an analogue of vasoactive intestinal peptide (VIP), which was first discovered in 1970, and that Relief and its predecessor companies have been working on the development of aviptadil for nearly 20 years. The parties’ collaboration agreement with respect to the development and commercialization of aviptadil also covers the formulation of aviptadil being used by NeuroRx, as well as any intellectual property that NeuroRx may obtain with respect to such formulation, and that under such agreement, NeuroRx is obligated to cross-license such formulation, as well as all related intellectual property, to Relieve.f.
One of the purported breaches of the collaboration agreement mentioned in Relief’s prior breach of contract case against NeuroRx and its CEO, Jonathan Javitt, is NeuroRx’s failure to cross-license their formulation of aviptadil to Relief.
“In our previous guidance to investors, we advised that there were no filed patents protecting the manufacture of ZYESAMI. With the filing of this patent and the inventions described within, we at NRx believe we have a path to a long term commercial life for a stable and pharmaceutically active form of VIP as an innovative drug. Although, for obvious reasons, our initial focus has been the use of VIP in lung disease caused by COVID-19, we are now considering potential use of ZYESAMI in non COVID-related lung disease, liver disease, eye disease, and organ transplantation. We are deeply grateful to our partners at Nephron Pharmaceuticals for working with us and embracing the painstaking work required to bring a seventy-year-old dormant drug to life,”said Prof Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals.